About Circular Genomics
Circular Genomics is a Healthcare company based in Albuquerque (United States) founded in 2021 by Nikolaos Mellios. RNA-based diagnostics and therapeutics for depression are developed and provided. Circular Genomics has raised $45.59 million across 7 funding rounds from investors including The University of New Mexico, Alzheimer's Drug Discovery and Mountain Group Partners. The company has 1 employees. Circular Genomics offers products and services including MindLight. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Circular Genomics Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Circular Genomics was founded in 2021 in Albuquerque, United States, within the biotechnology sector focused on genomics. RNA-based diagnostics and therapeutics are offered to address depression and related psychiatric conditions. A circular RNA-based genomic assay has been developed as a biomarker to predict therapeutic responses in individuals with neurological disorders. Operations center on advancing these tools for clinical applications.
- Headquarters Albuquerque, United States
- Employees 1
- Founders Nikolaos Mellios
- SectorsHealthcare
- Email••••••••
- Website circulargenomics.com
- Social LinkedIn X Facebook Instagram
- Legal Name Circular Genomics Inc.
- Total Equity Funding$45.59M (USD)
in 7 rounds
- Latest Funding Round$15M (USD), Series A
Dec 2025
- InvestorsThe University of New Mexico
& 5 more
- Employee Count1
Products & Services of Circular Genomics
Circular Genomics offers a comprehensive portfolio of products and services, including MindLight.
Predicts patient response to antidepressants using circular RNA biomarkers.
Funding Insights of Circular Genomics
Circular Genomics has successfully raised a total of $45.59M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $15 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $45.59M
- Total Rounds 7
- Last Round Series A — $15M
- First Round $1.19M
(Aug 2021)
- Investors Count 6
All 7 funding rounds of Circular Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $15M | Series A | – | Mountain Group Partners | |
| Jul 2025 | $250,000 | Grant | – | – | |
| Jan 2024 | $8.3M | Series A | – | Mountain Group Partners | |
| Jan 2024 | $8.3M | Series A | – | – | – |
| Jan 2024 | $8.3M | Series A | – | – | – |
| Dec 2021 | $4.5M | Seed | – | Cottonwood Technology Fund, Tramway Venture Partners | – |
| Aug 2021 | $1.19M | Seed | – | – | – |
6 investors in total: 6 institutional.
Investors in Circular Genomics
Circular Genomics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include The University of New Mexico, Alzheimer's Drug Discovery and Mountain Group Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is directed toward life sciences and technology sectors. | mtngp.com | Nashville, United States | ||
| cottonwood.vc | ||||
Venture capital investments are focused on life sciences companies. | tramwayventures.com | Albuquerque, United States | ||
Higher education, research, and student support services are provided. | 1889 | unm.edu | United States | |
Drugs for Alzheimer's prevention, treatment, and cure are discovered. | 1998 | alzdiscovery.org | New York, United States | |
| hip.fund |
Investor details for Circular Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Circular Genomics
3 people are tracked at Circular Genomics (2 in leadership, 1 in team); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Nikolaos Mellios | Co-Founder | Leadership |
Dave Karlander | Chief Commercial Officer | Leadership |
Carlos Cruchaga | For Research Of Circular Rnas In Alzheimer’s Disease | Team |
Complete people profiles for Circular Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Circular Genomics
3 dated milestones of Circular Genomics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Circular Genomics is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Series A, of $15.0M.
Competitors of Circular Genomics
Circular Genomics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Circular Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Circular Genomics
The website of Circular Genomics (circulargenomics.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▼ 6.5% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Circular Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Circular Genomics
Complete news archive for Circular Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Circular Genomics
Circular Genomics was founded in 2021.
Circular Genomics is headquartered in Albuquerque, United States. It is registered at Albuquerque, New Mexico, United States.
Circular Genomics is a funded company, having raised a total of $45.59M across 7 funding rounds to date. The company's 1st funding round was a Seed of $1.19M, raised on Aug 2021.
Circular Genomics has 1 employees.
Circular Genomics was founded in 2021 in Albuquerque, United States, within the biotechnology sector focused on genomics. RNA-based diagnostics and therapeutics are offered to address depression and related psychiatric conditions. A circular RNA-based genomic assay has been developed as a biomarker to predict therapeutic responses in individuals with neurological disorders. Operations center on advancing these tools for clinical applications.
Circular Genomics offers MindLight.
Circular Genomics has 6 investors. Key investors include The University of New Mexico, Alzheimer's Drug Discovery, Mountain Group Partners, Cottonwood Technology Fund, and Tramway Ventures.
Circular Genomics operates through Circular Genomics Inc..